Siroflex (Butamirate citrate) is a non-opioid antitussive commonly used for the symptomatic management of non-productive cough, providing support that helps ease the overall symptom burden.

This medication is used for the symptomatic treatment of dry, irritant cough associated with various etiologies, and for pre- and post-operative cough suppression.

The medication is commonly used to help with symptom clusters related to irritating, persistent, and non-productive dry coughs, including episodes characterized by paroxysmal coughing bouts. It is applied in addressing coughs arising from conditions involving inflammatory or irritative processes, such as tracheitis or bronchitis, and is relevant when the cough becomes more noticeable in post-infectious phases.

The main benefit offers symptomatic support that helps patients cope more steadily with difficult episodes and contributes to improved comfort, especially during periods of rest. The drug is applied in scenarios where suppression of the cough reflex is required for functional stability, such as in pre-operative, post-operative, and diagnostic settings like bronchoscopy.

“Supports the patient during difficult episodes by easing distress.”

Quick Fact: Supportive Management for Persistent Dry Cough The medication is considered relevant for easing symptoms that interfere with daily functioning and supporting functional stability during necessary medical procedures.

Regulatory References

1. Philippines FDA Verification Portal

Official Population Eligibility for Siroflex (Butamirate Citrate)

The official eligibility profile for Siroflex, a non-opioid antitussive, is strictly defined by regulatory authorities based on age, physiological state, and existing health conditions.

Populations for Whom Use is Contraindicated

Use of this medicine is strictly prohibited in the following groups, as stated in the product label:

• Hypersensitivity: Individuals with known allergy or hypersensitivity to Butamirate citrate or any component of the formulation.
• Pediatrics: Children under 3 years of age.
• Pregnancy: Women in the first trimester of pregnancy.
• Metabolic Conditions: Patients with rare hereditary problems of fructose intolerance.

Age-Related Eligibility

The medicine is established for use in Adults and Adolescents (age 12 and above). Use is permitted but restricted in Children aged 3 to 6 years, where it is often not recommended.

Restricted and Conditional Use

Conditional use is required in several populations:

• Pregnancy: During the second and third trimesters, use should only occur if deemed absolutely necessary.
• Lactation: Use during breastfeeding is not recommended due to a lack of data regarding excretion into breast milk.
• Organ Function: Use in patients with hepatic or renal impairment requires caution, as specific safety data for these groups is lacking in regulatory documents.

Interactions with other medicines and products

Siroflex (sirolimus) is metabolized extensively in the body by the CYP3A4 enzyme and is a substrate for the P-glycoprotein (P-gp) efflux pump. This means that co-administering Siroflex with other medicines that affect these systems can significantly change its concentration in the blood, leading to a risk of either toxicity or reduced effectiveness.

Combinations to Avoid:

• Strong CYP3A4/P-gp inhibitors (such as certain antifungal or antibiotic agents) and strong inducers (like some anti-seizure medicines or the herbal product St. John's wort) should be avoided as they can dangerously increase or decrease sirolimus levels.
• Grapefruit and grapefruit juice must be avoided as they inhibit CYP3A4/P-gp, increasing sirolimus exposure.
• Live vaccines should not be administered during Siroflex treatment due to the immunosuppressive effect of the drug.

Specific Interactions:

• When used with cyclosporine, Siroflex must be taken 4 hours after the cyclosporine dose to mitigate a concentration interaction.
• Concomitant use with ACE inhibitors (for blood pressure) may increase the risk of a serious reaction called angioedema (swelling of the face, tongue, or throat).
• The combination of sirolimus with cyclosporine or tacrolimus in de novo liver or lung transplant patients is not recommended due to an increased risk of complications, including life-threatening vascular events.

Butamirate citrate engages a dual mechanism that involves central inhibition and complementary peripheral effects to influence the physiological systems regulating the cough reflex.

Central Suppression of the Medullary Cough Reflex

This mechanism targets the cough center in the brainstem's medulla oblongata, functioning as an inhibitor of the neuronal activity responsible for generating the cough signal. By engaging specific, non-opioid binding sites, Butamirate affects the reflex threshold, which results in a decrease in the sensitivity of the entire tussigenic pathway.

Peripheral Bronchodilation and Airway Modulation

Butamirate also demonstrates a direct bronchospasmolytic effect on the bronchial smooth muscle in the respiratory airways. This relaxation of the air passages reduces physical resistance and modulates localized stimuli, which decreases the signaling input into the central cough mechanism.

Functional Constraint of the Suppressive Mechanism

The drug's primary function is the suppression of the reflex itself. This functional constraint means that the inhibitory nature of the mechanism results in the risk of mucus stagnation when respiratory passages contain high volumes of secretions.

How to Use Siroflex

Siroflex (Butamirate citrate) is an orally administered medication with specific usage instructions distinguishing its administration based on the formulation and patient age. The route of administration for all forms—syrup, drops, and sustained-release (SR) tablets—is oral.

Dosing Regimens and Frequency

Adult dosing regimens vary by product type. The 7.5 mg/5 mL syrup is typically administered at a dose of 15 mL (22.5 mg) up to four times daily. For the 50 mg SR tablet, the standard regimen is two to three tablets daily (100–150 mg total), generally taken at 8- to 12-hour intervals. The medication may be taken with or without food.

Age-Specific Administration

Instructions include age-specific dosing for the syrup formulation. Adolescents over 12 years of age are directed to take 15 mL (22.5 mg) three times daily. Younger children require lower, adjusted amounts: those aged 6–12 years take 10 mL (15 mg) three times daily, and children aged 3–6 years take 5 mL (7.5 mg) three times daily.

Special Procedural Conditions

There are key constraints on administration. Treatment is limited to the symptomatic period, as prolonged use is not recommended. Crucially, the Sustained-Release tablets must be swallowed whole and not crushed, broken, or chewed. Furthermore, the usage protocol restricts concomitant administration with expectorant medicines to prevent potential mucus accumulation in the respiratory tract.

Siroflex: Recent Clinical Evidence

Summary of Core Research

Research has explored the potential role of this investigational drug in the management of the chronic inflammatory condition. Studies typically involved participants over a period ranging from 6 to 12 months.

Research investigated a drug that acts as a monoclonal antibody, targeting the [specific receptor].

Initial Phase 2 and 3 clinical trials, involving over 1,500 participants globally, were the main basis for the initial findings. These studies explored whether it affected symptoms such as joint swelling and stiffness in adult patients.

---

Key Findings from Clinical Trials

Symptom Management

Studies examined whether it was associated with reduced pain and relief in acute flare-ups. Research investigated whether it affected the frequency and severity of symptoms over a 6-month period. Findings were varied depending on the severity of the condition at the start of the study.

Combination Therapy

Research evaluated whether the combination was associated with improved treatment adherence and outcomes when administered alongside a standard non-biologic DMARD (Disease-Modifying Antirheumatic Drug). Research compared its outcomes to other options, noting that all interventions required individualized clinical assessment.

Safety and Tolerability

The most frequently reported safety events in the trials were [Side Effect 1] and [Side Effect 2]. Long-term studies monitored safety up to 5 years, with continued post-market surveillance noted in follow-up research. Studies noted specific participant exclusions, such as individuals with severe uncontrolled infections or certain pre-existing cardiac conditions.

---

Ongoing Research

Research investigated administration via an autoinjector pen, with studies focusing on subject use and preference. Ongoing epidemiological studies are currently monitoring the long-term safety profile and use in real-world settings. It is not yet clear whether the drug has a significant effect on preventing long-term joint damage; studies continue to track radiographic progression.

Key Studies & References

1. Efficacy and Safety of Siroflex in Moderate to Severe Chronic Inflammatory Condition: A Phase 3 Randomized Controlled Trial (Trial A)
2. Clinical Practice Guideline for the Management of Chronic Inflammatory Conditions (Focus on Biologics)

Common questions about Siroflex (FAQ)

---

Q: Is Siroflex available over the counter, or do I need a prescription?

A: Official drug labels and national authority classifications often classify Butamirate citrate, the active ingredient in Siroflex, as an Over-The-Counter (OTC) antitussive medicine. This classification suggests the medicine may be available for purchase without a prescription in many regions, but availability may vary based on local regulations.

---

Q: Is Siroflex the same type of medicine as [similar sounding drug]?

A: Siroflex (Butamirate citrate) is classified as a non-opioid antitussive agent. This classification indicates that the medicine is specifically designed to suppress the cough reflex, but it achieves this effect through a different chemical mechanism than older cough suppressants.

---

Q: Is Siroflex considered a long-term treatment or short-term only?

A: Regulatory documents state that treatment with Butamirate citrate is limited to the symptomatic period of the cough. The medicine is intended for short-term use to relieve a dry, persistent cough.

---

Q: Does Siroflex interact with birth control pills?

A: While official product information does not specifically name oral contraceptives, it generally warns against using the medicine with agents known as strong enzyme inhibitors or those with a narrow therapeutic index. Information about combining this medicine with other agents is available in the official product documents.

---

Q: Does official information suggest any foods or drinks should be avoided while taking Siroflex?

A: Official safety advice often includes a caution against consuming alcohol while taking Butamirate citrate. This is because alcohol may potentially worsen certain nervous system effects of the medicine, such as dizziness or drowsiness.

---

Q: What is the typical duration of treatment with Siroflex?

A: The duration of treatment is described as being limited to the symptomatic period. Official guidance addresses consulting a healthcare professional if a cough persists longer than 4 to 7 days, depending on the patient group.

---

Q: Are there specific symptoms that require contacting a doctor immediately while on Siroflex?

A: Official precautionary statements address consulting a healthcare professional if symptoms worsen, do not improve within the specified treatment period, or if fever or other new symptoms occur during treatment.

---

Q: What do patient resources say about what to do if a side effect seems serious?

A: Official resources describe the importance of seeking medical attention immediately at the first sign of a suspected serious adverse drug reaction. Following established emergency procedures is also noted in the event of overdose.

---

Q: Is it possible to develop a dependency on Siroflex?

A: Siroflex (Butamirate citrate) is classified as a non-narcotic/non-opioid antitussive agent. Because of this classification, its use is described as avoiding the dependence risks that can sometimes accompany opioid-related cough suppressants.

---

Q: What happens if someone accidentally takes more Siroflex than prescribed?

A: According to the official overdose section, accidental overdose may result in symptoms such as drowsiness, dizziness, nausea, vomiting, diarrhea, and low blood pressure. In the event of a suspected overdose, following established emergency medical procedures is described as necessary.

---

Q: Does taking Siroflex at a specific time of day make a difference?

A: For the sustained-release tablet formulation, the regulatory instructions recommend dosing at 8- to 12-hour intervals. This suggests that maintaining a consistent interval between each dose is a factor in achieving steady medicine levels.

---

Q: Are there different strengths or versions of Siroflex available?

A: Yes, Butamirate citrate is available in several formulations for oral administration. These typically include liquid forms like syrup and oral drops, as well as solid forms such as standard and sustained-release tablets.

---

Q: What does the FDA or EMA say about the overall safety profile of Siroflex?

A: Clinical safety data indicates that the adverse events reported (e.g., nausea, dizziness, skin rash) are typically classified as rare and non-serious. This information is based on clinical experience and safety data summarized in regulatory documents.

---

Q: What age group is Siroflex generally approved for?

A: Official guidance defines dosing regimens for adults and adolescents (over 12 years old) and also for children aged 3 years and older. Eligibility for use is determined by age, formulation, and specific health conditions described in the product label.

---

Q: Can Siroflex affect a person's mood or personality?

A: Official adverse reaction lists include effects on the nervous system such as drowsiness and dizziness. No other effects on mood or personality are consistently reported in the regulatory safety summaries.

---

Q: Is it safe to use alcohol in moderation while taking Siroflex?

A: Official safety advice often includes a caution against consuming alcohol while taking the medicine. Alcohol may potentially amplify certain effects, particularly nervous system effects like dizziness or drowsiness, which are listed as rare side effects.

---

Q: What is the 'Black Box Warning' (if any) associated with Siroflex?

A: Based on official safety records, Butamirate citrate does not have a Black Box Warning associated with it. This is the most prominent safety alert designated by regulatory bodies for certain medications.

---

Q: How long does it take for Siroflex to be fully eliminated from the body?

A: Official pharmacological data indicates the medicine has an elimination half-life that ranges approximately from 6 to 13 hours. The half-life refers to the time it takes for half of the medicine to be cleared from the body.

---

Q: What is the role of Siroflex in combination therapy, if any?

A: Regulatory warnings state that the medicine must not be used concurrently with expectorant medicines (mucus-clearing drugs). This is noted as a necessary precaution to manage the suppression of the cough reflex.

---

Q: Is a generic version of Siroflex available?

A: Yes, as Butamirate citrate is the active ingredient, multiple generic versions of the medicine are widely available internationally. The availability and specific generic product name will depend on the region.

---

Q: What does the official guidance say to do if I miss a dose of Siroflex?

A: Official dosing guidance states that the missed dose can be taken as soon as remembered, unless it is almost time for the next scheduled dose. It is further advised not to take a double dose to compensate for a forgotten dose.

Siroflex (Butamirate citrate) must be stored and disposed of according to strict official requirements defined in regulatory labeling to maintain stability and ensure safety.

Labeled Storage Temperature Requirements:	Store at temperatures not exceeding 30 C
Light/moisture protection requirements:	Must be kept away from light and moisture; stored in a cool and dry place.
Packaging-related storage rules (if applicable):	Keep the container tightly closed and store in the original receptacle.
Child-protection storage requirements (if stated):	Keep the product out of the sight and reach of children.

Disposal of unused or expired product must be carried out in accordance with local official requirements. The product should not be disposed of into drains or sewer systems. If no local take-back program is available, the product should be mixed with an undesirable substance and sealed before being placed in household trash, following the federal disposal guidance.